Journal: NPJ Vaccines

Article Title: Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine

doi: 10.1038/s41541-025-01219-5

Figure Lengend Snippet: A Schematic illustration of the experimental protocol of preparation of dendritic cells (DCs) transduced with the replication-deficient, wild-type p53-expressing adenovirus Ad-p53 (Ad-p53 DCs). Bone marrow-derived cells isolated from the femur of BALB/c mice were incubated with GM-CSF (40 ng/mL) and IL-4 (10 ng/mL) for 5 days and then infected with Ad-p53 (100 MOI) for 2 days to obtain Ad-p53 DCs. Figures were generated using BioRender. B Expression of human p53 mRNA in control DCs and DCs infected with DL312 (100 MOI) or Ad-p53 (100 MOI) for 48 h. GAPDH was used as a control gene. C Representative photographs of expression of human p53 protein in DCs infected with Ad-p53 (100 MOI) for 72 h. Scale bars, 100 μm. D Expression of mature DC markers in Ad-p53 DCs. Control DCs and Ad-p53 DCs were subjected to flow cytometry for analysis of CD11c, CD86, MHC class-II (MHC-II), CD103, and CCR7 expression. The mean fluorescence intensity (MFI) for each protein was determined by calculating the difference between the MFI of the antibody- and control IgG-treated cells. Data are expressed as mean ± SD ( n = 3). Statistical significance was determined using one-way ANOVA followed by Tukey’s comparison test. *** P < 0.001; **** P < 0.0001.

Article Snippet: Rabbit anti-CD8a mAb (1:100, 4SM15; eBioscience, San Diego, CA, USA) and rabbit anti-CD11c mAb (1:350, 97585; Cell Signaling Technology) were used as primary antibodies.

Techniques: Transduction, Expressing, Derivative Assay, Isolation, Incubation, Infection, Generated, Control, Flow Cytometry, Fluorescence, Comparison

Journal: NPJ Vaccines

Article Title: Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine

doi: 10.1038/s41541-025-01219-5

Figure Lengend Snippet: A Representative photographs of immunohistochemical staining for CD8 + T cells and CD11c+ DCs in each group. Scale bars, 50 μm. B Percentage of CD8+ cells and CD11c+ cells calculated from five different randomly selected fields. C Percentage of CD8 + , CD8 + CD137 + , CD8 + CD69 + , CD8 + PD-1 + , and CD11c+ cells among live cells assessed using flow cytometry. Data are expressed as the mean ± SD ( n = 5). Statistical significance was determined using one-way ANOVA followed by Tukey’s comparison test. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Rabbit anti-CD8a mAb (1:100, 4SM15; eBioscience, San Diego, CA, USA) and rabbit anti-CD11c mAb (1:350, 97585; Cell Signaling Technology) were used as primary antibodies.

Techniques: Immunohistochemical staining, Staining, Flow Cytometry, Comparison

Journal: NPJ Vaccines

Article Title: Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine

doi: 10.1038/s41541-025-01219-5

Figure Lengend Snippet: A Combined effect of Ad-p53 DC and OBP-702 in the CT26 tumor model using athymic nude mice. Data are expressed as the mean tumor volume ± SD ( n = 5). B Combined effect of Ad-p53 DC and OBP-301 in the CT26 tumor model. Data are expressed as the mean tumor volume ± SD ( n = 6). C Difference in the growth of CT26 tumors between control and complete response (CR) mice. Combination therapy-treated CR mice and control mice were subcutaneously inoculated with CT26 cells. Data are expressed as the mean ± SD ( n = 3). D Growth curves for treated and untreated sites of control, Ad-p53 DC-treated, OBP-702-treated, and combination therapy (combo)-treated tumors in bilateral CT26 tumor models. Data are expressed as the mean ± SD ( n = 5). E Representative photographs of immunohistochemical staining for CD8 + T cells and CD11c+ DCs in each group. Scale bars, 50 μm. F Percentage of CD8+ cells and CD11c+ cells calculated from five different randomly selected fields. Data are expressed as the mean ± SD ( n = 5). Statistical significance was determined using one-way ANOVA followed by Tukey’s comparison test. * P < 0.05; ** P < 0.01; **** P < 0.0001.

Article Snippet: Rabbit anti-CD8a mAb (1:100, 4SM15; eBioscience, San Diego, CA, USA) and rabbit anti-CD11c mAb (1:350, 97585; Cell Signaling Technology) were used as primary antibodies.

Techniques: Control, Immunohistochemical staining, Staining, Comparison

Journal: NPJ Vaccines

Article Title: Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine

doi: 10.1038/s41541-025-01219-5

Figure Lengend Snippet: A Viability of MC38 cells was assessed using an XTT assay 3 days after OBP-702 treatment at the indicated MOIs. Cell viability was calculated relative to that of mock-infected cells, which were set as 1.0. B Expression of human p53 mRNA in MC38 cells before and after infection with OBP-702 (100 MOI) for 24 h. Data are expressed as mean ± SD ( n = 3). C Whole-cell lysates of MC38 cells before and after infection with OBP-702 (100 MOI) for 24 h were subjected to Western blot analysis of mouse p53, human p53, and β-actin expression. D Growth curves of control and Ad-p53 DC-treated tumors. Data are expressed as mean ± SD ( n = 3). E Schematic illustration of the MC38 tumor model experimental protocol. Figures were generated using BioRender. F Photographs of tumors in each group. G Growth curves of control, Ad-p53 DC-treated, OBP-702-treated, and combination therapy (combo)-treated tumors. H Representative photographs of immunohistochemical staining for CD8 + T cells and CD11c+ DCs in each group. Scale bars, 50 μm. I Percentage of CD8+ cells and CD11c+ cells calculated from five different randomly selected fields. Data are expressed as the mean ± SD ( n = 5). J CD8 + T cells isolated from splenocytes of control and treated mice were co-cultured with MC38 cells for 24 h, and the amount of extracellular LDH released from tumor cells was determined. The statistical significance of differences between two groups or three groups was determined using the Student t -test or one-way ANOVA followed by Tukey’s comparison test, respectively. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, not significant.

Article Snippet: Rabbit anti-CD8a mAb (1:100, 4SM15; eBioscience, San Diego, CA, USA) and rabbit anti-CD11c mAb (1:350, 97585; Cell Signaling Technology) were used as primary antibodies.

Techniques: XTT Assay, Infection, Expressing, Western Blot, Control, Generated, Immunohistochemical staining, Staining, Isolation, Cell Culture, Comparison